Vertex Pharmaceuticals Strengthens in the Cystic Fibrosis Space
Vertex Pharmaceuticals (VRTX) develops medicines for life-threatening diseases and is presently focused on developing drugs for cystic fibrosis and sickle-cell disease, partnering with CRISPR Therapeutics (CRSP) for the latter. Vertex’s Orkambi, Kalydeco, and Symdeko are top drugs in the cystic fibrosis market. Vertex stock’s 52-week low is $136.50, which it reached on December 7, 2017.